

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): MARCH 27, 2007

MARSHALL EDWARDS, INC.  
(Exact name of registrant as specified in its charter)

DELAWARE  
(State or other jurisdiction of  
incorporation or organization)

000-50484  
(Commission File Number)

51-0407811  
(I.R.S. Employer Identification No.)

140 WICKS ROAD, NORTH RYDE, NSW, 2113 AUSTRALIA  
(Address of principal executive offices) (Zip Code)

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (011) 61 2 8877-6196

NOT APPLICABLE  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to  
simultaneously satisfy the filing obligation of the registrant under any of the  
following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17  
CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR  
240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the  
Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the  
Exchange Act (17 CFR 240.13e-4(c))

ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;  
APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN  
OFFICERS.

On March 27, 2007, at a regularly scheduled meeting of the Board of Directors (the "Board") of Marshall Edwards, Inc. (the "Company"), the Board elected William Rueckert to serve as a director of the Company, effective as of March 27, 2007. The Board has determined that Mr. Rueckert meets the requirements of Nasdaq as an independent director. Mr. Rueckert will serve until the 2007 Annual Meeting of the Stockholders of the Company, at which time he will stand for re-election.

The Company's press release announcing Mr. Rueckert's election to the Board is attached hereto as Exhibit 99.1. The press release inadvertently states that Novogen Limited owns 82% of the Company. Novogen Limited owns 78.1% of the Company.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release issued by Marshall Edwards, Inc. dated as of March 28, 2007.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MARSHALL EDWARDS, INC.

By: /s/ David R. Seaton

-----  
David R. Seaton  
Chief Financial Officer  
(Duly Authorized Officer and Principal  
Financial Officer)

Dated: March 30, 2007

## Index to Exhibits

Exhibit No.	Description
99.1	Press Release issued by Marshall Edwards, Inc. dated as of March 28, 2007.

Marshall Edwards, Inc.

CONTACT: David Sheon - 202 518-6384 (USA)  
Mr. Christopher Naughton (CEO, Marshall Edwards, Inc)  
- +612 8878 6196 (Australia)

FOR IMMEDIATE RELEASE

NEW BOARD APPOINTMENT AT MARSHALL EDWARDS, INC.

Sydney: March 28, 2007 - Marshall Edwards, Inc is pleased to announce the appointment of Mr. William Rueckert to its Board of Directors

Mr. Rueckert is president and director of Rosow & Company, a private investment firm based in Connecticut since 1990 and is the Managing Member of Oyster Management Group LLC investment fund. Mr. Rueckert is a Director of Emergency Filtration Products, Inc. a public manufacturer and marketer of respiratory filtration devices and is a Director of Glycotex, Inc. an 83% owned unlisted subsidiary of Novogen Limited. Prior to his current positions, Mr. Rueckert has been president and director of Eastern Capital Development, LLC since 1999, treasurer of Moore & Munger, Inc. a company with interests in the petroleum and resort development industries, from 1988 until 1990, and was president of United States Oil Company, a publicly traded oil exploration business, from 1981 to 1988. Among his many civic associations, Mr. Rueckert is director and president of the Cleveland H. Dodge Foundation, a private philanthropic organization in New York City and chairman of the Board of the Trustees of Teachers College, Columbia University.

Welcoming Mr. Rueckert to the board, Marshall Edwards' Chief Executive Officer, Mr. Christopher Naughton, said his particular expertise and experience would bring additional strong commercial acumen to the board .

"Bill Rueckert also has an extensive US investment banking network which will benefit and enhance the existing Marshall Edwards' financial advisory relationships". Mr. Naughton said.

Mr. William Rueckert joins the MEI board of directors which includes Professor Bryan Williams (Chairman) Mr. Naughton (CEO), Professor Paul Nestel AO, Professor Graham Kelly and Messrs Philip Johnston and Stephen Breckenridge.

Incorporated in the US State of Delaware, Marshall Edwards, Inc. is 82 per cent owned by ASX and NASDAQ listed pharmaceutical company, Novogen Limited from which it licences phenoxodiol, and its shares are traded in the US on NASDAQ (Code: MSHL). More information on phenoxodiol and on the company can be found at [www.marshalledwardsinc.com](http://www.marshalledwardsinc.com) and [www.novogen.com](http://www.novogen.com)

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties,

including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.